Thyroglobulin and human thyroid cancer

Clinica Chimica Acta

Volumn 388, Issue 1-2, 2008, Pages 15-21

  Lin, Jen Der ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Fine needle aspiration; Immunohistological staining; Sodium iodide symporter; Thyroid transcription factor

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; LIOTHYRONINE; RECOMBINANT PROTEIN; THYROGLOBULIN; THYROID TRANSCRIPTION FACTOR 1; THYROXINE; TRANSCRIPTION FACTOR PAX8;

ASPIRATION BIOPSY; BIOCHEMISTRY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CELL DIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL HYPOTHYROIDISM; DIAGNOSTIC VALUE; FOLLOW UP; GENE EXPRESSION REGULATION; GENE MUTATION; GOITER; HORMONE SYNTHESIS; HUMAN; METASTASIS POTENTIAL; MOLECULAR WEIGHT; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SECRETION; RADIODIAGNOSIS; RADIOISOTOPE THERAPY; REVIEW; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID FOLLICLE; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME; WHOLE BODY SCINTISCANNING;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEALTH; HUMANS; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS;

EID: 37249069651     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.11.002     Document Type: Review

References (67)

1. Harach H.R., and Franssila K.O. Thyroglobulin immunostaining in follicular thyroid carcinoma: relationship to the degree of differentiation and cell type. Histopathology 13 (1988) 43-54
2. Pilotti S., Collini P., Del Bo R., Cattoretti G., Pierotti M.A., and Rilke F. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. Am J Surg Pathol 18 (1994) 1054-1064
3. Gong Y., and Krishnamurthy S. Fine-needle aspiration of an unusual case of poorly differentiated insular carcinoma of the thyroid. Diagn Cytopathol 32 (2005) 103-107
4. Bejarano P.A., Nikiforov Y.E., Swenson E.S., and Biddinger P.W. Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. Appl Immunohistochem Mol Morphol 8 (2000) 189-194
5. Basolo F., Pisaturo F., Pollina L.E., et al. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10 (2000) 19-23
6. Guarino E., Tarantini B., Pilli T., et al. Presurgical serum thyroglobulin has no prognostic value in papillary thyroid cancer. Thyroid 15 (2005) 1041-1045
7. Lin J.D., Huang M.J., Hsu R.S., et al. Significance of post-operative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol 80 (2002) 45-51
8. van de Graaf S.A., Pauws E., de Vijlder J.J., and Ris-Stalpers C.R. The revised 8307 base pair coding sequence of human thyroglobulin transiently expressed in eukaryotic cells. Eur J Endocrinol 136 (1997) 508-515
9. Yang S.X., Pollock H.G., and Rawitch A.B. Glycosylation in human thyroglobulin: location of the N-linked oligosaccharide units and comparison with bovine thyroglobulin. Arch Biochem Biophys 327 (1996) 61-70
10. van de Graaf S.A., Ris-Stalpers C., Pauws E., Mendive F.M., Targovnik H.M., and de Vijlder J.J.M. Structure update: up to date with human thyroglobulin. J Endocrinol 170 (2001) 307-321
11. Campagnolo M., Pesaresi A., Zelezetsky I., et al. Structural studies on Pax-8 Prd domain/DNA complex. J Biomol Struct Dyn 24 (2007) 429-442
12. Dohan O., De la Vieja A., Paroder V., et al. The sodium/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr Rev 24 (2003) 48-77
13. Damante G., Tell G., and Di Lauro R. A unique combination of transcription factors controls differentiation of thyroid cells. Prog Nucleic Acid Res Mol Biol 66 (2001) 307-356
14. De Felice M., and Di Lauro R. Thyroid development and its disorders: genetics and molecular mechanisms. Endocr Rev 25 (2004) 722-746
15. Plachov D., Chowdhury K., Walther C., Simon D., Guenet J.L., and Gruss P. Pax8, a murine paired box gene expressed in the developing excretory system and thyroid gland. Development 110 (1990) 643-651
16. Lazzaro D., Price M., De Felice M., and Di Lauro R. The transcription factor TTF-1 is expressed at the onset of thyroid and lung morphogenesis and in restricted regions of the fetal brain. Development 113 (1991) 1093-1104
17. Kimura S., Hara Y., Pineau T., et al. The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev 10 (1996) 60-69
18. Zannini M., Avantaggiato V., Biffali E., et al. TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation. EMBO J 16 (1997) 3185-3197
19. Sinclair A.J., Lonigro R., Civitareale D., Ghibelli L., and Di Lauro R. The tissue-specific expression of the thyroglobulin gene requires interaction between thyroid-specific and ubiquitous factors. Eur J Biochem 193 (1990) 311-318
20. Santisteban P., Acebron A., Polycarpou-Schwarz M., and Di Lauro R. Insulin and insulin-like growth factor I regulate a thyroid-specific nuclear protein that binds to the thyroglobulin promoter. Mol Endocrinol 6 (1992) 1310-1317
21. Kambe F., Nomura Y., Okamoto T., and Seo H. Redox regulation of thyroid-transcription factors, Pax8 and TTF-1, is involved in their increased DNA-binding activities by thyrotropin in rat thyroid FRTL-5 cells. Mol Endocrinol 10 (1996) 801-812
22. Velez M.L., Costamagna E., Kimura E.T., et al. Bacterial lipopolysarccharide stimulates the thyrotropin-dependent thyroglobulin gene expression at the transcriptional level by involving the transcription factors thyroid transcription factor-1 and paired box domain transcription factor 8. Endocrinology 147 (2006) 3260-3275
23. Hishinuma A., Takamatsu J., Ohyama Y., et al. Two novel cysteine substitutions (C1263R and C1995S) of thyroglobulin cause a defect in intracellular transport of thyroglobulin in patients with congentital goiter and the variant type of adenomatous goiter. J Clin Endocrinol Metab 84 (1999) 1438-1444
24. Alzahrani A.S., Baitei E.Y., Zou M., and Shi Y. Clinical case seminar: metastatic follicular thyroid carcinoma arising from congenital goiter as a result of a novel splice donor site mutation in the thyroglobulin gene. J Clin Endocrinol Metab 91 (2006) 740-746
25. Hishinuma A., Fukata S., Kakudo K., Murata Y., and Ieiri T. High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutation. Thyroid 15 (2005) 1079-1084
26. Rivolta C.M., and Targovnik H.M. Molecular advances in thyroglobulin disorders. Clin Chim Acta 374 (2006) 8-24
27. Kitanaka S., Takeda A., Sato U., et al. A novel compound heterozygous mutation in the thyroglobulin gene resulting in congenital goitrous hypothyroidism with high serum triiodothyronine levels. J Hum Genet 51 (2006) 379-382
28. Vono-Toniolo J., Rivolta C.M., Targovnik H.M., Medeiros-Neto G., and Kopp P. Naturally occurring mutations in the thyroglobulin gene. Thyroid 15 (2005) 1021-1033
29. Hishinuma A., Fukata S., Nishiyama S., et al. Haplotype analysis reveals founder effects of thyroglobulin gene mutations C1058R and C1977S in Japan. J Clin Endocrinol Metab 91 (2006) 3100-3104
30. Gutnisky V.J., Moya C.M., Rivolta C.M., et al. Two distinct compound heterozygous constellations (R277X/IVS34-1G>C and R227X/R1511X) in the thyroglobulin (TG) gene in affected individuals of a Brazilian kindred with congenital goiter and defective TG synthesis. J Clin Endocrinol Metab 89 (2004) 646-657
31. Morris H.P., Dalton A.J., and Green C.D. Malignant thyroid tumors occurring in the mouse after prolonged hormonal imbalance during the ingestion of thiouracil. J Clin Endocrinol Metab 11 (1951) 1281-1295
32. Luboshitzky R., Lavi I., and Ishay A. Serum thyroglobulin levels after fine-needle aspiration of thyroid nodules. Endocr Pract 12 (2006) 264-269
33. Iervasi A., Iervasi G., Carpi A., and Zucchelli G.C. Serum thyroglobulin measurement: clinical background and main methodological aspects with clinical impact. Biomed Pharmacother 60 (2006) 414-424
34. Christensen S.B., Bondeson L., Erisson U.B., and Lindholm K. Prediction of malignancy in the solitary thyroid nodule by physical examination, thyroid scan, fine-needle biopsy and serum thyroglobulin. A prospective study of 100 surgically treated patients. Acta Chir Scand 150 (1984) 433-439
35. Bennedbaek F.N., Perrild H., and Hegedus L. Diagnosis and treatment of the solitary thyroid nodule. Results of a Eurpean survey. Clin Endocrinol 50 (1999) 357-363
36. Tamizu A., Okumura Y., Sato S., et al. The usefulness of serum thyroglobulin levels and Tl-201 scintigraphy in differentiating between benign and malignant thyroid follicular lesions. Ann Nucl Med 16 (2002) 95-101
37. Morita M., Noguchi S., Kawamoto H., Tajiri J., Tamaru M., and Murakami N. Thyroglobulin and lactic dehydrogenase isoenzymes in cystic fluid of thyroid nodules. Endocr J 41 (1994) 227-233
38. Panza N., Lombardi G., De Rosa M., Pacilio G., Lapenta L., and Salvatore M. High serum thyroglobulin levels. Diagnostic indicators in patients with metastases from unknown primary sites. Cancer 620 (1987) 2233-2236
39. Ito N., Yokota M., Nagaike C., et al. Simultaneous expression of keratan sulphate epitope (a sulphated poly-N-acetyllactosamine) and blood group ABH antigens in papillary carcinomas of the human thyroid gland. Histochem J 28 (1996) 613-623
40. Ito N., Yokota M., Kawahara S., et al. Histochemical demonstration of different types of poly-N-acetyllactosamine structures in human thyroid neoplasms using lectins and endo-β-galactosidase digestion. Histochem J 27 (1995) 620-629
41. Shimizu K., Nakamura K., Kobatake S., et al. The clinical utility of Lens culinaris agglutinin-reactive thyroglobulin ratio in serum for distinguishing benign from malignant conditions of the thyroid. Clin Chim Acta 379 (2007) 101-104
42. Heemstra K.A., Liu Y.Y., Stokkel M., et al. Serum thyroglobulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol 66 (2007) 58-64
43. Kloos R.T., and Mazzaferri E.L. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 90 (2005) 5047-5057
44. Leboulleux S., Rubino C., Baudin E., et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 90 (2005) 5023-5029
45. Eustatia-Rutten C.F., Smit J.W., Romijn J.A., et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol 61 (2004) 61-74
46. Zerva B., Koutsikos J., Palestidis C., Kounadi E., and Gerali S. Value of thyroglobulin to (131)I uptake ratio in selection of initial therapy dose of (131)I in patients with differentiated thyroid carcinoma. Q J Nucl Med Mol Imaging 50 (2006) 348-354
47. Baudin E., Do Cao C., Cailleux A.F., Leboulleux S., Travagli J.P., and Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88 (2003) 1107-1111
48. Huang S.H., Wang P.W., Huang Y.E., et al. Sequential follow-up of serum thyroglobulin and whole body scan in thyroid cancer patients without initial metastasis. Thyroid 16 (2006) 1273-1278
49. Mazzaferri E.L., and Kloos R.T. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 10 (2000) 767-778
50. Potzi C., Moameni A., Karanikas G., et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol 65 (2006) 519-523
51. David A., Blotta A., Rossi R., et al. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 15 (2005) 267-273
52. Smallridge R.C., Meek S.E., Morgan M.A., et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 92 (2007) 82-87
53. Giovanella L., Ceriani L., Ghelfo A., et al. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Clin Chem Lab Med 44 (2006) 648-652
54. Torlontano M., Crocetti U., Augello G., et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 91 (2006) 60-63
55. Kebebew E., and Reiff E. Patients with differentiated thyroid cancer have a venous gradient in thyroglobulin levels. Cancer 109 (2007) 1078-1081
56. Shammas A., Degirmenci B., Mountz J.M., et al. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-Differentiated thyroid cancer. J Nucl Med 48 (2007) 221-226
57. Boi F., Baghino G., Atzeni F., Lai M.L., Faa G., and Mariotti S. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab 91 (2006) 1364-1369
58. Watkinson J.C., Franklyn J.A., and Olliff J.F. Detection and surgical treatment of cervical lymph nodes in differentiated thyroid cancer. Thyroid 16 (2006) 187-194
59. Ers V., Galant C., Malaise J., Rahier J., and Daumerie C. Axillary lymph node metastasis in recurrence of papillary thyroid carcinoma: a case report. Wien Klin Wochenschr 118 (2006) 124-127
60. Lin J.D. Papillary thyroid carcinoma with lymph node metastases. Growth Factors 25 (2007) 41-49
61. Lin J D. Papillary thyroid carcinoma with lymph node metastases. Growth Factors 2007 (in press ).
62. Cignarelli M., Ambrosi A., Marino A., et al. Diagnostic utility of thyroglobulin detection in fine-needle aspiration of cervical cystic metastatic lymph nodes from papillary thyroid cancer with negative cytology. Thyroid 13 (2003) 1163-1167
63. Gerard A.C., Daumerie C., Mestdagh C., et al. Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. J Clin Endocrinol Metab 88 (2003) 4977-4983
64. Kebebew E., Peng M., Treseler P.A., et al. Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells. J Clin Endocrinol Metab 90 (2004) 5906-5907
65. Singh B., Bollmann R., Ahmadzadehfar H., Biersack H.J., and Ezziddin S. Unusual case of well-differentiated papillary thyroid carcinoma lacking thyroglobulin expression while still concentrating radioiodine. Br J Radiol 79 (2006) e84-e87
66. Furuya F., Shimura H., Suzuki H., et al. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated ans anaplastic thyroid cancer cells by expression of sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145 (2004) 2865-2875
67. Wang C.Y., Zhong W.B., Chang T.C., Lai S.M., and Tsai Y.F. Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88 (2003) 3021-3026